Results 21 to 30 of about 887,943 (333)
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
New England Journal of Medicine, 2022 BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia ...
P. Montesinos +15 more
semanticscholar +1 more source
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
New England Journal of Medicine, 2020 BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo +29 more
semanticscholar +1 more source
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal, 2021 Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian +8 more
semanticscholar +1 more source
Advances in acute myeloid leukemia
British medical journal, 2021 Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar +1 more source
Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]
Einstein (São Paulo), 2011 Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman +12 more
doaj +3 more sources
CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]
, 2008 The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi +55 more
core +3 more sources
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]
, 2019 Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M +4 more
core +1 more source
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Leukemia, 2020 The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus +33 more
semanticscholar +1 more source
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
The Journal of the National Comprehensive Cancer Network, 2021 The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding ...
D. Pollyea +33 more
semanticscholar +1 more source
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]
, 2018 The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core +1 more source